The benefits of Oxbryta no longer outweigh the risks, Pfizer says.
More Stories
Treasury yields edge lower ahead of PCE inflation report
Bond yields edged lower Friday as traders awaited a U.S. inflation report.
PayPal’s stock is having its best year since 2020, and this is a big reason why
When PayPal CEO Alex Chriss took over a year ago, investors questioned whether the company had a future. Now he...
Wall Street grows more optimistic about Tesla sales. Should you?
China sales are likely to be the highlight of Tesla’s upcoming deliveries data.
‘I am beyond hurt’: If my husband and his son die, his house will go to his daughter-in-law. Is this nuts?
‘His son, who is a high earner, will need to wait for his inheritance until after I pass away’
Bristol-Myers Squibb stock jumps on schizophrenia drug approval
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.
Chinese stocks could surge higher as investors get ‘FOMO,’ Goldman Sachs says
International investors are getting increasingly concerned about missing out on the rally that was sparked by the unveiling of the...